Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Kahl S, Pernille Ofstad A, Zinman B, et al.
Diabetes Obes Metab. 2022 Feb 15.
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Kahl S, Pernille Ofstad A, Zinman B, et al.
Diabetes Obes Metab. 2022 Feb 15.
Leggi
Kong YW, Venkatesh N, Paldus B et al
Diabetes Technol Ther. Pub. online 15 February 2022
Leggi
Visser M, Mathieu C, Gillard P
Diabetes Technol Ther. Pub. online 14 February 2022
Leggi
Fraszczyk E, Spijkerman AMW, Snieder H, et al.
Diabetologia. Pub. online 15 February 2022.
Leggi
Dahl D, Onishi Y, Norwood P, et al.
JAMA. 2022;327(6):534-545.
Leggi
Chipkin SR
JAMA. 2022;327(6):529-530.
Leggi
Dawwas GK, Flory JH, Hennessy S et al.
Diabetes Care. 2022;dc212177
Leggi
Moss AC, Robert AJ, Yi-Frazier JP, et al.
Diabetes Care. 2022;dc211553
Leggi
Raverdy V, Cohen RV, Caiazzo R, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00005-5
Leggi
Cousin E, Duncan BB, Stein C, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(21)00349-1
Leggi